← Back to Clinical Trials
RecruitingPhase 2NCT06451120

Platelet Rich Plasma Injections In Young And Old Human Subjects

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionOsteoarthritis
SponsorUniversity of California, San Francisco
Study TypeINTERVENTIONAL
PhasePhase 2
Enrollment60
SexALL
Min Age18 Years
Max Age70 Years
Start Date2024-06-01
Completion2027-02-16
Interventions
Platelet-Rich Plasma (PRP) InjectionsCentrifugeControl saline injection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is a randomized, double-blind, placebo-controlled phase 2 study with a secondary crossover phase at the end of the initial trial to ensure all subjects receive one PRP injection. The goal is to identify what proteins change in the blood following repeated intraarticular knee PRP injections in patients with knee osteoarthritis. The objective is to determine the protein changes resulting from a single autologous PRP injection (5 mL) in comparison to a normal saline control. About 60 subjects will take part in this study by two age groups at UCSF into the following arms: Arm A: PRP injection; Arm B: normal saline injection control. The study aims to demonstrate what benefits PRP has on knee osteoarthritis and methods to best achieve biologic effects. Subjects with a diagnosis of knee osteoarthritis ages 18-45 and 46-70 years old presenting to a University Based sports medicine clinic will be screened for potential eligibility. Subjects who meet all qualifying requirements will be recruited from UCSF's orthopedic and primary care clinics. Subjects will be on study for up to 26 weeks Screening: up to 14 days Treatment: injection of PRP or normal saline; subjects can cross over at week 12 to a PRP if originally in the control injection group Follow-up: 2 weeks post-baseline injection, 12 weeks postbaseline, (14 weeks if crossover patient), 26 weeks.

Eligibility Criteria

Inclusion Criteria 1. Grade 1-3 KL score will be recruited; 2. Symptoms of knee osteoarthritis for at least 3 months before presentation in one knee; 3. Have symptomatic complaints from osteoarthritis pain in no other joint affecting the hips, ankles or unaffected knee; 4. Will be able to attend and perform physical therapy. 5. English-speaking Exclusion Criteria 1\. Patients will be excluded if: 1. Received injection therapy for knee osteoarthritis in the past 6 months 2. Have signs of concomitant osteoarthritis of 1 or more other major joints of the lower extremities that impair their daily activity level 3. History of septic arthritis 4. Have underwent a previous knee surgery specifically for osteoarthritis or osteochondral defects less than 1 year before randomization (i.e. autograft or allograft surgery 5. High tibial osteotomy, partial knee replacement, patellar resurfacing), total knee replacement or existing surgical hardware in the knee 6. Patient with platelet disorders, blee

Related Trials